Project Grant R01HL184127
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $594K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $149,214 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lipid-loaded macrophages in atherosclerotic plaque inflammation. The recipient will characterize the metabolic landscape and cell fate decisions of atheroma-derived macrophages under lipid loading, examining how lipid-associated macrophages release extracellular adenosine triphosphate as a pro-inflammatory signaling...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $820,111 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the cell-specific role of the CD40L-CD40 co-stimulatory dyad in modulating atherosclerosis and natural antibody production. The project examines how CD40 expression on B1 cells—innate B cells that produce atheroprotective anti-oxidation-specific-epitope (OSE) immunoglobulin M—protects against atherosclerosis by...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $1,562,026 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a mechanistic and causal inference analysis of propofol-associated hypertriglyceridemia (P-HTG). The research will establish a prospective observational cohort with systematic triglyceride monitoring and comprehensive lipoprotein phenotyping to define P-HTG epidemiology, distinguish clearance-defect from production-excess...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $242,100 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate treatment-resistant insomnia, with work completed by July 31, 2028. Mayo Clinic will define and quantify the prevalence of treatment-resistant insomnia in a real-world clinical sample using electronic health record data from the Mayo Clinic Biobank and Mayo Clinic Tapestry Project, supplemented by chart review validation....
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- Federal Grant Award Summary Mayo Clinic received a $783,661 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 5, 2025, with completion scheduled for August 31, 2026. The award funds a pragmatic, randomized clinical trial evaluating the effectiveness and safety of oral midodrine as a vasopressor-sparing agent in patients with sepsis-associated hypotension. The study seeks to reduce intensive...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic Arizona $1,665,204 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how P2RX7-expressing CD4+ T cells control virus-induced lung sequelae. The research defines how severe respiratory infections such as influenza and SARS-CoV-2 promote pathogenic lung CD4+ T cell accumulation that perpetuates long-term lung damage, including the irreversible organ dysfunction observed in long COVID...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $240,600 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate the combined immunomodulatory effects of macrolides and corticosteroids in hospitalized patients with community-acquired pneumonia. The study investigates how macrolide antibiotics and corticosteroids, often coadministered in community-acquired pneumonia treatment, affect inflammatory markers and clinical outcomes....
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $761,573 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a pragmatic, open-label, randomized clinical trial comparing the effectiveness and safety of azithromycin versus doxycycline in combination with beta-lactam therapy for hospitalized adult patients with community-acquired pneumonia. The trial will enroll and randomize 1,120 adult patients hospitalized with community-acquired...